This is the authors' abstract. We don't add key points for this paper.
The development of antibodies against infliximab is associated with an increased risk of infusion reactions and a reduced duration of response to treatment. Concomitant immunosuppressive therapy reduces the magnitude of the immunogenic response.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Baert et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: